- Home
- CZNC vs STRO Comparison
CZNC vs STRO Comparison
Compare CZNC & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CZNC | STRO |
|---|---|---|
| Founded | 1864 | 2003 |
| Country | United States | United States |
| Employees | 460 | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.4M | 381.1M |
| IPO Year | 2009 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CZNC | STRO |
|---|---|---|
| Price | $25.96 | $20.91 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $23.50 | ★ $31.33 |
| AVG Volume (30 Days) | 59.5K | ★ 289.1K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.81 | N/A |
| Revenue | N/A | ★ $38,419,000.00 |
| Revenue This Year | $3.11 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.10 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.87 | $0.72 |
| 52 Week High | $26.26 | $43.85 |
Technical Indicators
Market Signals| Indicator | CZNC | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 74.31 | 32.83 |
| Support Level | $22.73 | $19.11 |
| Resistance Level | N/A | $27.16 |
| Average True Range (ATR) | 0.64 | 1.82 |
| MACD | 0.02 | -0.21 |
| Stochastic Oscillator | 82.86 | 26.86 |
Price Performance
Historical ComparisonAbout CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.